Bariatric surgery produces the largest and most durable weight loss medicine has, and a share of patients still regain. That combination has turned a GLP-1 prescription after an operation into one of the fastest-growing uses of the drug class. It is usually bought the way anything else here is bought — on a cash plan, from a page that knows nothing about the surgery. What the treatment costs across a course matters here for the same reason it does in the withdrawal trials, and what the evidence actually covers is narrower than the demand.
Why the question exists
A 2026 society statement on this exact problem describes a subset of patients who experience inadequate weight loss, termed non-response, or weight recurrence after an initial loss. Either can bring back the metabolic disease the operation was meant to resolve.[1]
The scale shows up in who gets prescribed something afterward. One observational study followed 121 patients started on a weight medication after primary or conversional surgery. The group had regained a median of 9.7 kg, which represented 27.9% of the total body weight they had previously lost (IQR, 15.7 to 57.8).[2] That is the population the rest of this page describes.
The one randomized trial
The trial recruited adults at least one year after metabolic surgery who had lost 20% or less of their body weight since the day of the operation and had a suboptimal nutrient-stimulated GLP-1 response. Two London hospitals randomized 70 participants 1:1 to liraglutide 3.0 mg daily or placebo, stratified by procedure and by diabetes status, with both arms on a 500-kcal daily energy deficit.[3]
Over 24 weeks, estimated mean percentage body weight change was −8.82% on liraglutide against −0.54% on placebo. The mean difference was −8.03% (95% CI, −10.39 to −5.66; P < .001). Adverse events, predominantly gastrointestinal, were more frequent on the drug — 80% against 57% — with no serious adverse events and no treatment-related deaths.[3]
Read the design as carefully as the result. Seventy people, 24 weeks, two hospitals, a daily molecule that most sellers no longer supply, and a cohort selected for a blunted GLP-1 response rather than for regain in general. It is a real answer to a narrow question, and it is the only randomized answer this field has.
What the cohorts add, and what they cost in certainty
A 2026 systematic review searched three databases for studies of liraglutide, semaglutide and tirzepatide in adults treated at least a year after metabolic surgery. It included 27 papers and meta-analyzed 19. At twelve months, total weight loss was 9.22% with liraglutide and 9.02% with semaglutide. At six months, tirzepatide led semaglutide by a mean difference of 4.23% in total weight loss.[4]
Reported side effects were mostly mild and gastrointestinal, with no serious adverse events observed. The review’s own caution is the sentence to carry away: substantial heterogeneity across the included studies means the pooled figures should be read with care.[4]
An earlier meta-analysis confined to liraglutide gathered 16 studies and 881 individuals with follow-up ranging from three months to four years. Among patients treated, 65.8 per 100 lost more than 5% of total body weight and 26.77 per 100 lost more than 10%.[5] Proportions like those are more useful than a mean, because they say how often the treatment did something worth paying for.
Tirzepatide’s record here is one retrospective series
A 2025 analysis followed 21 post-bariatric patients without type 2 diabetes who had insufficient weight loss or weight regain after sleeve gastrectomy or gastric bypass, through six months of adjunctive tirzepatide. Mean total weight loss was 12.0% ± 3.4% (p < 0.001). Every patient lost at least 5%, 76.5% lost at least 10%, and 23.5% lost at least 15%.[6]
The same analysis reported a body-composition difference between its two subgroups: patients with insufficient weight loss lost less fat-free mass at three months than those with weight regain (p < 0.05).[6]Lean tissue is a live question for anyone who has already lost a great deal of weight once, and the pooled figures for adults generally are in the muscle article.
The trial that would settle it is only now enrolling
The GRABS trial is the first randomized study of a GLP-1 receptor agonist in patients with persistent obesity after Roux-en-Y gastric bypass. It compares 24 weeks of tirzepatide plus standard care against standard care alone, with total percent weight change as the primary outcome. Eligible patients are aged 25 to 65, carry a body-mass index of 30 or above, and enroll at least twelve months after surgery.[7]
Its published baseline paper reports 33 enrolled and a final cohort of 28, at a median age of 42.0 years, a pre-surgery body-mass index of 48.3 and a randomization body-mass index of 36.0.[7] Outcomes have not been published. Anyone quoting a randomized tirzepatide figure for this population today is quoting something that does not exist yet.
Where the professional bodies have landed
The 2026 society statement reviews the whole menu: revisional surgery after bypass or sleeve, endoscopic options such as transoral outlet reduction, and obesity-modifying medications. It records that semaglutide and tirzepatide have demonstrated weight loss in post-surgical patients, and calls the newer medications a major advance.[1]
It also sets a limit that applies to every figure on this page. Across all modalities, variability in outcomes and high loss to follow-up limit the quality of the data, and management is described as individualized and multidisciplinary rather than algorithmic.[1] A decision of this kind belongs with the surgical team that holds the operative record.
What these numbers are not
They are not a study of what most sellers dispense. Every trial and cohort above used an approved product, and whether a compounded preparation behaves identically has not been established — the distinction is set out in the compounding article. Pricing for the approved and compounded routes is on the semaglutide board.
They are also not a study of the doses being sold. The randomized trial used liraglutide 3.0 mg daily, and the largest observational series used semaglutide 1.0 mg, which sits below the 2.4 mg weight-management maximum described in the dose article.
And altered anatomy changes more than absorption. Nutrition, micronutrient status and gastrointestinal tolerance after a bypass or a sleeve are surgical questions, and a telehealth intake form that never asks about a prior operation has not collected what a prescriber needs. How figures on this site get established before publication is described in the methodology.